CN105566485A - Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof - Google Patents
Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof Download PDFInfo
- Publication number
- CN105566485A CN105566485A CN201510997219.8A CN201510997219A CN105566485A CN 105566485 A CN105566485 A CN 105566485A CN 201510997219 A CN201510997219 A CN 201510997219A CN 105566485 A CN105566485 A CN 105566485A
- Authority
- CN
- China
- Prior art keywords
- epk
- polypeptide
- tumor
- application
- signal path
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an anti-tumor polypeptide capable of targeted inhibition of an EPK signal channel and an application thereof; a nucleic acid sequence of the polypeptide is derived from an important nucleic acid fragment in the EPK signal channel of tumor cells; the polypeptide is a polypeptide which can effectively and accurately inhibit the tumor cell activity through the unique nucleic acid sequence. According to the anti-tumor polypeptide capable of targeted inhibition of the EPK signal channel and the application thereof, the polypeptide can block EPK nuclear localization to inhibit growth of the tumor cells, and at the same time, has no effect on cells without tumor transformation; study results show that the polypeptide can block the EPK nuclear localization or become an effective target site for targeted treatment of tumor, and thus the anticancer effect can be greatly improved.
Description
Technical field
The present invention relates to a kind of tumor protein p53 and application thereof, be specifically related to a kind of tumor protein p53 and application thereof of energy targeted inhibition EPK signal path, belong to field of biomedicine technology.
Background technology
Cancer cells is a kind of cell of variation, is to produce the pathogeny of cancer, and cancer cells is different from normal cell, has indeterminate growth, conversion and transfer three feature greatly, can infinite multiplication destroy normal cell tissue.Therefore be difficult to eliminate the inside and outside of cancer cells and hide the reverse factor that self cannot overcome and cannot get rid of, this is its feature, also be its shortcoming, create its unstable, EPK signal path works orderly in neoplastic lesion one large feature is that it nuclear translocation can occur, and EPK can carry out nuclear location plays for it and promote that cell proliferation function is extremely important.And be positioned in tenuigenin the EPK signal path being in state of activation and can induce immediate feedback loop isoreactivity, therefore need a peptide species to carry out targeted inhibition EPK signal path, so just can play antineoplastic effect.
Summary of the invention
The technical problem to be solved in the present invention overcomes existing defect, a kind of tumor protein p53 and application thereof of energy targeted inhibition EPK signal path are provided, EPK nuclear location and then inhibition tumor cell growth can be blocked by this polypeptide, the cell that tumor transformation does not occur is not affected simultaneously, this result of study shows to block the Effective target site that EPK nuclear location maybe can become targeting therapy on tumor, anticancer effect can be improved greatly, effectively can solve the problem in background technology.
In order to solve the problems of the technologies described above, the invention provides following technical scheme:
The invention provides a kind of tumor protein p53 and application thereof of energy targeted inhibition EPK signal path, the nucleotide sequence of this polypeptide is from the important nucleic acid fragment in the EPK signal path of tumour cell, and this polypeptide described is can the polypeptide of the effective activity of inhibition tumor cell accurately by its distinctive nucleotide sequence.
As a preferred technical solution of the present invention, this polypeptide described is the polypeptide that its coding has antitumour activity.
As a preferred technical solution of the present invention, this polypeptide described is the polypeptide that accurately can suppress EPK signal path.
As a preferred technical solution of the present invention, this polypeptide described can block the polypeptide that EPK nuclear location maybe can become the Effective target site of targeting therapy on tumor.
As a preferred technical solution of the present invention, this polypeptide described is the polypeptide with nuclear location.
As a preferred technical solution of the present invention, this polypeptide described is the interactional polypeptide that can block between importin7 and EPK.
As a preferred technical solution of the present invention, this polypeptide described can be implanted in malignant melanoma cell or other cancer cells and cultivate.
As a preferred technical solution of the present invention, this polypeptide described can inject the animal that canceration occurs and cultivate observation.
The beneficial effect that the present invention reaches is: a kind of tumor protein p53 of energy targeted inhibition EPK signal path and application thereof, EPK nuclear location and then inhibition tumor cell growth can be blocked by this polypeptide, the cell that tumor transformation does not occur is not affected simultaneously, this result of study shows to block the Effective target site that EPK nuclear location maybe can become targeting therapy on tumor, anticancer effect can be improved greatly, and be the polypeptide with nuclear location by this polypeptide, effectively can play the effect of target location, and can block by this polypeptide the polypeptide that EPK nuclear location maybe can become the Effective target site of targeting therapy on tumor, antitumous effect can be improved greatly.
Embodiment
Below in conjunction with embodiment, the preferred embodiments of the present invention are described, should be appreciated that preferred embodiment described herein is only for instruction and explanation of the present invention, is not intended to limit the present invention.
Embodiment 1:
First look for the small white mouse of the generation canceration of more than 10, then observe and record the cell situation of canceration in each Mice respectively, and then inject this appropriate polypeptide to the position of small white mouse generation canceration, then the growing environment that small white mouse one is suitable is given, observe the situation of cancerous tumor cell in Mice after a period of time, then the outcome record of observation is got off.
With the method for the present embodiment, effectively can detect the antitumous effect of this polypeptide, after this polypeptide is injected canceration position, the meeting of this polypeptide and cancerous tumor cell react, and effectively can suppress the activity of cancerous tumor cell, and can be killed.
Embodiment 2:
First look for the small white mouse of the generation canceration of more than 10, then the cell of some cancerations is taken out, then the EPK signal path in cancerous tumor cell is dispelled, then the cancerous tumor cell after these being processed is put in the reactor, then in reactor, this appropriate polypeptide is added, then reactor is placed in a good environment, carry out observed and recorded after a while, and then some complete cancerous tumor cells are put into reactor, then this appropriate polypeptide is added to the inside, then reactor is placed in a good environment, carries out observed and recorded after a while.
With the method for the present embodiment, effectively can detect this polypeptide target to locating effect, if the cancer cell-apoptosis in complete cancer cells reactor, and there is not any change in the cancer cells of dispelling EPK signal path, thus can effectively check out this polypeptide target to location inhibition.
Last it is noted that the foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, although with reference to previous embodiment to invention has been detailed description, for a person skilled in the art, it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature.Within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (8)
1. the tumor protein p53 of an energy targeted inhibition EPK signal path and application thereof, it is characterized in that, the nucleotide sequence of this polypeptide is from the important nucleic acid fragment in the EPK signal path of tumour cell, and this polypeptide described is can the polypeptide of the effective activity of inhibition tumor cell accurately by its distinctive nucleotide sequence.
2. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described is the polypeptide that its coding has antitumour activity.
3. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described is the polypeptide that accurately can suppress EPK signal path.
4. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described can block the polypeptide that EPK nuclear location maybe can become the Effective target site of targeting therapy on tumor.
5. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described is the polypeptide with nuclear location.
6. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described is the interactional polypeptide that can block between importin7 and EPK.
7. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described can be implanted in malignant melanoma cell or other cancer cells and cultivate.
8. according to claim 1 a kind of can the tumor protein p53 of targeted inhibition EPK signal path and application thereof, it is characterized in that, this polypeptide described can inject the animal that canceration occurs and cultivate and observe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510997219.8A CN105566485A (en) | 2015-12-29 | 2015-12-29 | Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510997219.8A CN105566485A (en) | 2015-12-29 | 2015-12-29 | Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105566485A true CN105566485A (en) | 2016-05-11 |
Family
ID=55877168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510997219.8A Pending CN105566485A (en) | 2015-12-29 | 2015-12-29 | Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105566485A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003042371A2 (en) * | 2001-11-15 | 2003-05-22 | Millennium Pharmaceuticals, Inc. | 55053, a novel human eukaryotic kinase and uses therefor |
| JP2005229815A (en) * | 2004-02-17 | 2005-09-02 | Japan Science & Technology Agency | Intranuclear localization nucleic acid structure |
| CN101157728A (en) * | 2006-10-08 | 2008-04-09 | 中国科学院上海生命科学研究院 | ERK2 combination polypeptide and preparation thereof |
| WO2008104979A3 (en) * | 2007-02-28 | 2010-09-02 | Yeda Research And Development Co. Ltd. | Nuclear targeting sequences |
| KR20140071736A (en) * | 2012-12-04 | 2014-06-12 | 세종대학교산학협력단 | Composition for preventing or treating cancer disease comprising monoclonal antibody 57-C11 |
| CN104327172A (en) * | 2014-09-30 | 2015-02-04 | 中国科学院微生物研究所 | Erk signal pathway inhibitor |
| WO2015040609A1 (en) * | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
| CN104610435A (en) * | 2015-01-26 | 2015-05-13 | 上海交通大学医学院附属新华医院 | Antitumor polypeptide for targeted inhibition on ERK signal channel and application of antitumor polypeptide |
| CN105012952A (en) * | 2015-08-13 | 2015-11-04 | 中国科学院动物研究所 | CXCL13 oncoprotein and application of targeted medicine for CXCL13 oncoprotein in tumor aspect |
-
2015
- 2015-12-29 CN CN201510997219.8A patent/CN105566485A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003042371A2 (en) * | 2001-11-15 | 2003-05-22 | Millennium Pharmaceuticals, Inc. | 55053, a novel human eukaryotic kinase and uses therefor |
| JP2005229815A (en) * | 2004-02-17 | 2005-09-02 | Japan Science & Technology Agency | Intranuclear localization nucleic acid structure |
| CN101157728A (en) * | 2006-10-08 | 2008-04-09 | 中国科学院上海生命科学研究院 | ERK2 combination polypeptide and preparation thereof |
| WO2008104979A3 (en) * | 2007-02-28 | 2010-09-02 | Yeda Research And Development Co. Ltd. | Nuclear targeting sequences |
| KR20140071736A (en) * | 2012-12-04 | 2014-06-12 | 세종대학교산학협력단 | Composition for preventing or treating cancer disease comprising monoclonal antibody 57-C11 |
| WO2015040609A1 (en) * | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
| CN104327172A (en) * | 2014-09-30 | 2015-02-04 | 中国科学院微生物研究所 | Erk signal pathway inhibitor |
| CN104610435A (en) * | 2015-01-26 | 2015-05-13 | 上海交通大学医学院附属新华医院 | Antitumor polypeptide for targeted inhibition on ERK signal channel and application of antitumor polypeptide |
| CN105012952A (en) * | 2015-08-13 | 2015-11-04 | 中国科学院动物研究所 | CXCL13 oncoprotein and application of targeted medicine for CXCL13 oncoprotein in tumor aspect |
Non-Patent Citations (3)
| Title |
|---|
| GALINA SCHEVZOV ET AL.: "Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments", 《MOLECULAR BIOLOGY OF THE CELL》 * |
| 娄喜余: "Raf-1抑制剂的设计、合成与生物活性研究和奥拉帕尼结构修饰", 《中国优秀硕士学位论文全文数据库》 * |
| 王潇等: "细胞核质转运受体Importin β家族与转运调控", 《细胞生物学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Demény et al. | The PARP enzyme family and the hallmarks of cancer part 1. cell intrinsic hallmarks | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| Allen et al. | Quo vadis radiotherapy? Technological advances and the rising problems in cancer management | |
| US20160000504A1 (en) | Method for training immune cells using millimeter wave therapy | |
| CN105566485A (en) | Anti-tumor polypeptide capable of targeted inhibition of EPK signal channel and application thereof | |
| RU2015128766A (en) | PARTICULAR VIRUS-ORIGINED PARTICLES AND THEIR APPLICATION | |
| CN115227834A (en) | Method for specifically killing cancer cells by combining gene editing technology with DNA damage repair inhibitor | |
| Salem et al. | Management strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review | |
| Abdollahi | Beneficial effects of cellular autofluorescence following ionization radiation: hypothetical approaches for radiation protection and enhancing radiotherapy effectiveness | |
| Senan | Stereotactic body radiotherapy: do central lung tumors still represent a ‘no-fly zone’? | |
| WO2014040605A1 (en) | New peptides as a monotherapy in malignancy control | |
| CN105330749B (en) | The building and application of radio therapy sensitization fused polypeptide | |
| Takashima et al. | The Effects of Radiation Dose Heterogeneity on the Tumor Microenvironment and Anti-Tumor Immunity | |
| Lui et al. | Proton Radiation Therapy for Stage IIA/IIB Testicular Seminoma | |
| Survival | Melanoma Brain Metastases & Treatment-Resistant Metabolism | |
| CN101898012A (en) | Method for enhancing high intensity focused ultrasound (HIFU) induced anti-tumor immune response | |
| Edhemovic et al. | Electrochemotherapy of colorectal liver metastases–trial update | |
| THAKUR et al. | Ovarian Cancer Treatment by Suicide Gene Therapy: Beauty of Nanotechnology in Medicine | |
| Que et al. | Radiotherapy for the Treatment of Giant Cell Tumor of the Spine: A Report of 3 Cases and Review of the Literature | |
| Tariq et al. | CRISPR and Cancer: From Bench to Clinic | |
| Cisneros | Cancer stem cell as a promising therapeutic treatment | |
| Sepiashvili | On the possible role of incomplete phagocytosis in carcinogenesis and metastasis | |
| Tozzi et al. | EP-1457 Moderate hypofractionation and SIB with volumetric modulated arc therapy (RapidArc) for anal cancer | |
| O'Dwyer et al. | The Role of Imaging in the Era of Targeted Therapy for Lung Cancer | |
| Wang et al. | Microbeam radiation therapy: a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |